Details of the Active Pharmaceutical Ingredient (API)
General Information of API (ID: D00052) | |||||
---|---|---|---|---|---|
Name |
Avanafil
|
||||
Synonyms |
Click to Show/Hide the Synonyms of This API
Avanafil; 330784-47-9; STENDRA; TA 1790; TA-1790; UNII-DR5S136IVO; CHEBI:66876; (S)-4-((3-Chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide; DR5S136IVO; (S)-2-(2-Hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[(2-pyrimidinylmethyl)carbamoyl]pyrimidine; (S)-4-(3-Chloro-4-methoxybenzylamino)-2-(2-hydroxymethylpyrrolidin-1-yl)-N-pyrimidin-2-ylmethyl-5-pyrimidinecarboxamide; Spedra; 4-[(3-chloro-4-methoxybenzyl)amino]-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide; 4-[(3-chloro-4-methoxyphenyl)methylamino]-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide; (S)-4-[(3-Chloro-4-methoxybenzyl)amino]-2-[2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2pyrimidinylmethyl)-5-pyrimidinecarboxamide; Stendra (TN); Avanafil [USAN:INN]; Zepeed; ine-5-carboxamide; 4-((3-Chloro-4-methoxybenzyl)amino)-2-((2S)-2-(hydroxymethyl)pyrrolidin-1-yl)-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide; Spedra (TN); Avanafil (USAN/INN); SCHEMBL118799; GTPL7448; CHEMBL1963681; DTXSID50186727; BDBM50036629; MFCD11977961; ZINC11677857; AKOS024462448; CCG-229896; DB06237; PB28365; VI-0162; NCGC00386241-01; AS-20106; HY-18252; SW219217-1; D03217; Q-4413; AB01565827_02; J-019006; Q2873270; BRD-K65781196-001-01-4; (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(2-pyrimidylmethyl)carbamoyl]-pyrimidine; (S)-4-[(3-Chlor-4-methoxybenzyl)amino]-2-[2-(hydroxymethyl)-1- pyrrolidinyl]-N-(2-pyrimidinylmethyl)-5-pyrimidinecarboxamid; 4-[(3-chloranyl-4-methoxy-phenyl)methylamino]-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-(pyrimidin-2-ylmethyl)pyrimid; 4-[(3-chloranyl-4-methoxy-phenyl)methylamino]-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-(pyrimidin-2-ylmethyl)pyrimid ine-5-carboxamide; 5-Pyrimidinecarboxamide, 4-(((3-chloro-4-methoxyphenyl)methyl)amino)-2-((2S)-2-(hydroxymethyl)-1-pyrrolidinyl)-N-(2-pyrimidinylmethyl)-; Avanafil; (S)-4-chloro-6-((3-chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide
|
||||
Clinical Status |
Approved
|
||||
Disease Indication | Erectile dysfunction | ICD-11: HA01 | [1] | ||
PubChem CID | |||||
Formula |
C23H26ClN7O3
|
||||
Canonical SMILES |
COC1=C(C=C(C=C1)CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCC[C@H]4CO)Cl
|
||||
InChI |
1S/C23H26ClN7O3/c1-34-19-6-5-15(10-18(19)24)11-27-21-17(22(33)28-13-20-25-7-3-8-26-20)12-29-23(30-21)31-9-2-4-16(31)14-32/h3,5-8,10,12,16,32H,2,4,9,11,13-14H2,1H3,(H,28,33)(H,27,29,30)/t16-/m0/s1
|
||||
InChIKey |
WEAJZXNPAWBCOA-INIZCTEOSA-N
|
||||
Click to Show/Hide the Molecular Data (Structure/Property) of This API | |||||
Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=9869929"></iframe>
|
||||
3D MOL | 2D MOL | ||||
Physicochemical Properties | Molecular Weight | 483.9 | Topological Polar Surface Area | 125 | |
XlogP | 2.6 | Complexity | 642 | ||
Heavy Atom Count | 34 | Rotatable Bond Count | 9 | ||
Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 9 | ||
Full List of Drug Formulations (DFMs) Containing This API | ||||||
---|---|---|---|---|---|---|
Avanafil 100 mg tablet | Click to Show/Hide the Full List of Formulation(s): 2 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Calcium carbonate; Fumaric acid; Magnesium stearate; Mannitol; Ferric oxide yellow; Hydroxypropyl cellulose (type h)
|
|||||
Dosage Form | Oral Tablet | |||||
Company | VIVUS | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Calcium carbonate | DIG Info | Carbonic anhydrase IX (Ki = 8600 nM) | [2] | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [3] | |||
Fumaric acid | DIG Info | HIF-prolyl hydroxylase 2 (IC50 = 19000 nM) | [4] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Calcium carbonate; Fumaric acid; Magnesium stearate; Mannitol; Ferric oxide yellow; Hydroxypropyl cellulose, unspecified; Low-substituted hydroxypropyl cellulose (11% hydroxypropyl 130000 mw)
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Mist Pharmaceuticals | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Calcium carbonate | DIG Info | Carbonic anhydrase IX (Ki = 8600 nM) | [2] | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [3] | |||
Fumaric acid | DIG Info | HIF-prolyl hydroxylase 2 (IC50 = 19000 nM) | [4] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Avanafil 200 mg tablet | Click to Show/Hide the Full List of Formulation(s): 2 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Calcium carbonate; Fumaric acid; Magnesium stearate; Mannitol; Ferric oxide yellow; Hydroxypropyl cellulose (type h)
|
|||||
Dosage Form | Oral Tablet | |||||
Company | VIVUS | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Calcium carbonate | DIG Info | Carbonic anhydrase IX (Ki = 8600 nM) | [2] | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [3] | |||
Fumaric acid | DIG Info | HIF-prolyl hydroxylase 2 (IC50 = 19000 nM) | [4] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Calcium carbonate; Fumaric acid; Magnesium stearate; Mannitol; Ferric oxide yellow; Hydroxypropyl cellulose, unspecified; Low-substituted hydroxypropyl cellulose (11% hydroxypropyl 130000 mw)
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Mist Pharmaceuticals | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Calcium carbonate | DIG Info | Carbonic anhydrase IX (Ki = 8600 nM) | [2] | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [3] | |||
Fumaric acid | DIG Info | HIF-prolyl hydroxylase 2 (IC50 = 19000 nM) | [4] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Avanafil 50 mg tablet | Click to Show/Hide the Full List of Formulation(s): 2 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Calcium carbonate; Fumaric acid; Magnesium stearate; Mannitol; Ferric oxide yellow; Hydroxypropyl cellulose (type h)
|
|||||
Dosage Form | Oral Tablet | |||||
Company | VIVUS | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Calcium carbonate | DIG Info | Carbonic anhydrase IX (Ki = 8600 nM) | [2] | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [3] | |||
Fumaric acid | DIG Info | HIF-prolyl hydroxylase 2 (IC50 = 19000 nM) | [4] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Calcium carbonate; Fumaric acid; Magnesium stearate; Mannitol; Ferric oxide yellow; Hydroxypropyl cellulose, unspecified; Low-substituted hydroxypropyl cellulose (11% hydroxypropyl 130000 mw)
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Mist Pharmaceuticals | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Calcium carbonate | DIG Info | Carbonic anhydrase IX (Ki = 8600 nM) | [2] | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [3] | |||
Fumaric acid | DIG Info | HIF-prolyl hydroxylase 2 (IC50 = 19000 nM) | [4] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.